Impact of Proactive Medication Review and Electronic Symptom Monitoring on Quality of Life and Costs in Adults Undergoing Oral Cancer Treatment

What this Trial Is About

Researchers are evaluating the impact on quality of life and economic outcomes of combining a scheduled consultation with a hospital clinical pharmacist and electronic patient-reported outcomes ePRO monitoring for patients undergoing oral cancer therapies. The study focuses on patients with metastatic or locally advanced cancer starting oral therapy, addressing issues like drug interactions, side effects, and the gap between patient and physician reporting of symptoms. Improving detection of drug interactions and monitoring toxicities aims to enhance patient care and treatment adherence. Participants are randomly assigned to either a group receiving proactive medication assessment with the hospital pharmacist plus follow-up using the THESS electronic monitoring system or to standard care without these interventions. The study involves scheduled consultations to detect potential drug interactions and inform patients about their treatments, alongside weekly symptom reporting via the THESS app. This approach integrates therapeutic follow-up and clinical information collection to better manage treatment toxicities. During the study, patients will be closely monitored for changes in quality of life, toxicity levels, treatment adherence, and patient satisfaction over up to 18 months. Assessments include patient-reported symptoms, medication adherence, prescription changes, and economic evaluations such as cost of care and budget impact analysis. Data collection occurs regularly at intervals up to 18 months, allowing researchers to measure time until a 5-point decrease in quality of life and other health outcomes, ensuring comprehensive monitoring throughout the study period.

Quality of Life and Economic Repercussions of Combining Proactive Medication Assessment and Electronic Monitoring of Toxicities in Subjects Undergoing Oral Cancer Therapy